<p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <em>ALK</em> Gene Have Durable Responses to ALK Kinase Inhibitors</p>Alexa B. Schrock, Siraj M. Ali, Mark R. Rosenzweig et al.|Lung Cancer Targets and Therapy|2020Cited by 3